Zoology, Bio and Pharma Research
Content Available at www.saapjournals.org
(An International Online Peer-Reviewed Journal) ISSN (O): XXXX-XXXX

Review Article
OPEN ACCESS

BIOCHEMICAL AND PHARMACOLOGICAL FOUNDATIONS OF REGENERATIVE MEDICINE: MOLECULAR MECHANISMS, THERAPEUTIC STRATEGIES, AND CLINICAL PERSPECTIVE

ZAINAB A. H. ALEBADY[1], FATIMA H. WALI[2]

[1]Department of Pathological analysis, College of Science, University of AL-Qadisiyah, AL-Diwaniyah, Iraq
[2]Department of Chemistry, College of Science, University of AL-Qadisiyah, AL-Diwaniyah, Iraq.

Article History: Received: 05 Oct 2025, Revised: 11 Nov 2025, Accepted: 24 Nov 2025

***Corresponding Author**
Zainab A. H. Alebady

Abstract
Regenerative medicine is a field that focus on repairing damaged tissues and organs by using the natural ability of the body to heal, instead of only treating the symptoms. It combine different areas such as biology, pharmacology, tissue engineering and molecular medicine to develop new treatments for diseases that were difficult to treat before. Recently, adding pharmacology to regenerative medicine, which is called regenerative pharmacology, allow scientists to control how cells behave, how signaling pathways work and how the tissue environment develop. This help in improving the effectiveness of regenerative treatments. This review explains the main biochemical and pharmacological concepts related to regenerative medicine, including molecular mechanisms, drug-based approaches and some clinical applications. It also discusses current challenges, safety issues and future directions, and shows how pharmacology can improve the safety and effectiveness of regenerative therapies.

Keywords: *Biochemical signaling, tissue engineering, stem cells, regenerative medicine, regenerative pharmacology, molecular therapies and molecular mechanisms.*

INTRODUCTION

Modern medicine is moving beyond only treating symptoms and try to restore the normal function of tissues. Regenerative medicine is a field that focus on repairing, replacing or regenerating damaged tissues and organs by using the body natural healing ability [1,2]. It combine several areas such as biochemistry, molecular biology, cell biology, pharmacology and tissue engineering to create treatments that are more precise and effective compared to standard therapies [1].

One of the major step in regenerative medicine was the discovery of stem cells. These cells have the ability to renew themself and differentiate into many types of specialized cells [3]. This discovery lead to the development of new approaches such as cell-based therapies, engineered biomaterials and bioactive molecules that support tissue healing in a controlled manner. Recently, pharmacology become more important in this field because it help in controlling inflammation, regulating cell signaling and improving the tissue environment for better regeneration [4].

REGENERATIVE PHARMACOLOGY: CONCEPT AND SCOPE

Regenerative pharmacology use drugs and other pharmacological tools to support tissue healing by acting on molecular and cellular processes involved in repair [5]. This field link regenerative medicine, which aim to restore normal tissue function, with traditional drug therapy that usually focus on symptom relief only.

One of the main goal of regenerative pharmacology is to control stem and progenitor cells so they can grow, survive and differentiate into the required cell types. It also work on regulating inflammation, oxidative stress and the local tissue environment, including blood vessel formation and the extracellular matrix, which are all important for tissue repair [5]. Different types of drugs are used, such as growth factors, cytokines, small molecules, as well as more advanced biologics and nanomaterials that can be delivered to specific target sites [6]. These agents may act directly on tissue cells or be combined with specially designed scaffolds to provide long-term effects. Research in regenerative pharmacology are being carried out in many body systems, including the heart, brain, muscles, endocrine organs and the urogenital system [7].

MOLECULAR AND BIOCHEMICAL MECHANISMS OF REGENERATION

Tissue regeneration happens when many biochemical and molecular processes work together. Cell growth, specialization, movement, and survival are controlled by signals from both outside and inside the cells.Several important signaling pathways play an important role in regeneration, including Wnt/β-catenin, TGF-β, FGF, VEGF, and CXCL12/CXCR4 [8-10].

Pharmacological treatments that target these pathways can help improve the body natural repair processes, increase the survival of transplanted or engineered cells, and support better integration of new tissues.In addition, controlling inflammation and oxidative stress is very important, because high level of inflammation or reactive oxygen species can negatively affect the regeneration process and reduce its overall success [11].

THERAPEUTIC OBJECTIVES OF REGENERATIVE PHARMACOLOGY

The main aim of regenerative pharmacology is to achieve long term tissue repair and restore normal function. This can be done through several connected approaches.

First, pharmacological agents can activate the body own repair mechanisms by stimulating resident stem and progenitor cells to proliferate and differentiate. This help to speed up tissue repair without the need of using external cell sources [12]. Second, regenerative pharmacology support tissue engineering methods by adding growth factors, cytokines, or small molecules into biomaterial scaffolds. This improve blood vessel formation, cell survival, and tissue integration after implantation [13].

Third, it also play a role in personalized medicine, where biochemical pathways are adjusted depending on each patient. When it is combined with autologous cell therapies, this can reduce immune rejection and improve treatment outcomes [14]. Finally, regenerative pharmacology contribute to innovation in drug discovery and screening, because regenerative models such as organ on chip systems and 3D tissue cultures allow high throughput drug testing, toxicity evaluation, and identification of new molecules that have regenerative potential [15].

PHARMACOLOGICAL STRATEGIES IN REGENERATIVE MEDICINE

Several pharmacological strategies have been developed to affect stem cell behavior and support tissue regeneration. These strategies include increasing stem cell numbers, mobilizing the body own progenitor cells, guiding cells to differentiate into specific cell types, and reprogramming cells into induced pluripotent stem cells (iPSCs) [16–18]. The use of small molecules, biologics, and scaffold technologies together provide flexible tools that help to improve tissue regeneration in a more controlled and effective way.

CLINICALLY APPROVED AND EMERGING REGENERATIVE THERAPIES

Several regenerative therapies have already receive regulatory approval, especially in areas such as wound healing and orthopedic treatments. These include autologous cell based products, engineered skin substitutes, and different therapies that are used for cartilage repair [19]. Pharmacological agents such as platelet derived growth factor (PDGF) and bone morphogenetic proteins (BMPs) are often incorporate to enhance tissue repair, stimulate angiogenesis, and improve osteogenesis [20].

Ongoing clinical trials continue to explore combination therapies that integrate multiple pharmacological agents with advanced biomaterials in order to optimize regenerative outcomes.

CLINICAL APPLICATIONS ACROSS DISEASE SYSTEMS

Regenerative pharmacology has been explored across a broad spectrum of diseases, including cardiovascular diseases (angiogenic pathway modulation for myocardial repair), neurological disorders (neurotrophic and cytokine-mediated neuroprotection), endocrine disorders (pancreatic islet regeneration in diabetes), musculoskeletal conditions, and liver or kidney diseases [21–24]. These applications demonstrate the versatility of regenerative pharmacology and its potential to address diseases historically difficult to treat.

REGENERATIVE PHARMACOLOGY CURRENT AND FUTURE PERCEPTIONS

These regenerative pharmacologic approaches have been applied to a number of disease condition some examples below:

- **The urogenital tract**: two important factors were mentioned recently in urologic tissue regeneration, Secretomes (is the set of proteins expressed by an organism and secreted into the extracellular space. In humans, this subset of the proteome encompasses 13-20% of all proteins, including cytokines, growth factors, extracellular matrix proteins and regulators, and shed receptors) and the CXCL12/VEGF axis (CXCL12 is The stromal cell-derived factor 1 (SDF1), also known as C-X-C motif chemokine 12 (CXCL12), is a chemokine protein that ubiquitously expressed in many tissues and cell types) (VEGF is Vascular endothelial growth factor is a signalling protein that promotes the growth of new blood vessels) [25,26].
- **The heart**: Cell therapy for myocardial regeneration has providing only temporary development in heart function. There have been multiple studies examining the effects of VEGF, CXCL12, angiopoietin, HGF (hepatocyte growth factor), anti-interleukin drugs and FGF(fibroblast growth factors) with varying results [27,28].

- **The brain**: preclinical and clinical studies were also done in brain diseases. Of these studies the use of VEGF for hypoxic brain injury , G-CSF for neural stem cell mobilization, HGF [27,29].
- **Diabetes**: islet transplantation and regeneration was afocus point for regenerative pharmacology; FGF-stimulated pancreas regeneration are under clinical investigations [30].
- **Liver**: current research with TGF-β 1(Transforming growth factor beta) being considered as an assistant therapy in liver diseases [31].
- **Bone and joint diseases**: n this field the researches focused on the proteins that are used to aid healing which also known as morphogenic proteins. The studies focused now on using in VEGF and TGF-β as an individual or assistant therapy for such diseases. Using of growth factors in bone transplantation is also under investigation [32].

Pharmacological knowledge cell-signaling pathways are of massive importance to overcome the issue of pathway overlapping, and assist in identifying treatment models that will optimize both the cell-based and tissue engineering-based approaches to tissue repair and replacement.

DISCUSSION

The integration of pharmacology into regenerative medicine is an important step toward restoring tissue and organ function in ways that traditional treatments cannot fully achieve. While regenerative medicine mainly focuses on stem cells, biomaterials, and tissue engineering, regenerative pharmacology adds more precision by allowing researchers and doctors to control cell behavior and molecular pathways in a more targeted way [4,5]. Tissue regeneration does not depend only on progenitor cells. Several other factors also affect this process. The local tissue environment, cellular signaling pathways, and general physiological conditions influence cell survival, differentiation, and integration into damaged tissue [8,9]. For regeneration to occur, different signaling pathways such as TGF-β, FGF, VEGF, CXCL12/CXCR4 and Wnt/β-catenin need to be activated and work together. Pharmacological approaches that target these pathways can help in improving tissue repair. For example, controlling TGF-β signaling may reduce fibrosis, while activation of VEGF signaling support the formation of new blood vessels. Some small molecules can also influence stem cell growth and differentiation [8-11].

Inflammation play an important role in the regeneration process. When inflammation become too strong or continue for long time, tissue healing may be delayed. Therefore, drugs that help in controlling inflammation can create more suitable conditions for tissue repair [11,12]. In clinical practice, regenerative pharmacology show positive effects in different organs, especially in the cardiovascular system, where enhancing blood vessel formation can support recovery after myocardial infarction. Neurotrophic signaling help in neurological recovery, and pharmacological support of pancreatic regeneration may help in treatment of endocrine diseases such as diabetes [21–23]. These approaches aim to solve the main cellular and molecular problems, rather than only controlling symptoms. Despite progress, challenges remain, including patient variability, off-target effects, incomplete tissue integration, and regulatory constraints [25]. Future directions emphasize precision pharmacology, combination therapies, advanced biomaterials, and integration of omics and artificial intelligence to optimize patient-specific regenerative interventions [26].Overall, regenerative pharmacology has the potential to shift medicine from symptomatic treatment to functional restoration, providing targeted, personalized, and durable therapies across organ systems [5,7,14].

CONCLUSION

The approach of regenerative medicine, act to propose tissues and organs to bioengineer by isolating, growing and then seeding cells from different sources for direct injection, or implantation. As the fact that cell, tissue and organ replacement and repair are an important issue around the world due to the lack in the ability to restore and replace or the shortage in the supplies. Regenerative Medicine is considered as a young yet promising science that could provide exactly what the medical field needs for such health condition. Regenerative Pharmacology can in fact offer an additional or replacements for the traditional methods of regenerative medicine. It might help to overcome many limitations facing the field of regenerative medicine including but not limiting to: immune rejection, cost and time required, shortage in supplies and many others. Researches on the new field of regenerative pharmacology are conducted all over the world with very wide expectations and high promises. [4-7,12-14].

REFERENCES

1. Haseltine, W.A., 2001. The emergence of regenerative medicine: a new field and a new society. *e-biomed: the journal of regenerative medicine*, *2*(4), pp.17-23.
2. Mason, C. and Dunnill, P., 2008. A brief definition of regenerative medicine.
3. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007 Dec 21;318(5858):1917-20. doi: 10.1126/science.1151526. Epub 2007 Nov 20. PMID: 18029452.
4. Christ, G.J., Saul, J.M., Furth, M.E. and Andersson, K.E., 2013. The pharmacology of regenerative

medicine. Pharmacological reviews, 65(3), pp.1091-1133.
5. Williams JK, Andersson KE. Regenerative pharmacology: recent developments and future perspectives. *Regen Med*. 2016;11(8):859-870. doi:10.2217/rme-2016-0108
6. Riazi, A.M., Kwon, S.Y. and Stanford, W.L., 2009. Stem cell sources for regenerative medicine. In *Stem Cells in Regenerative Medicine* (pp. 55-90). Humana Press.
7. Mao, A.S. and Mooney, D.J., 2015. Regenerative medicine: current therapies and future directions. *Proceedings of the National Academy of Sciences*, *112*(47), pp.14452-14459.
8. Giannelli, G., Mikulits, W., Dooley, S., Fabregat, I., Moustakas, A., ten Dijke, P., Portincasa, P., Winter, P., Janssen, R., Leporatti, S. and Herrera, B., 2016. The rationale for targeting TGF-β in chronic liver diseases. *European journal of clinical investigation*, *46*(4), pp.349-361.
9. Chen, B., Dodge, M.E., Tang, W., Lu, J., Ma, Z., Fan, C.W., Wei, S., Hao, W., Kilgore, J., Williams, N.S. and Roth, M.G., 2009. Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. *Nature chemical biology*, *5*(2), p.100.
10. Nagasawa, T., 2014. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. *Journal of molecular medicine*, *92*(5), pp.433-439.
11. Boros, P. and Miller, C.M., 1995. Hepatocyte growth factor: a multifunctional cytokine. *Lancet (British edition)*, *345*(8945), pp.293-295.
12. Boitano, A.E., Wang, J., Romeo, R., Bouchez, L.C., Parker, A.E., Sutton, S.E., Walker, J.R., Flaveny, C.A., Perdew, G.H., Denison, M.S. and Schultz, P.G., 2010. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. *Science*, *329*(5997), pp.1345-1348.
13. Walsh, G., 2010. Biopharmaceutical benchmarks 2010. *Nature biotechnology*, *28*(9), pp.917-924.
14. Evseenko, D., Zhu, Y., Schenke-Layland, K., Kuo, J., Latour, B., Ge, S., Scholes, J., Dravid, G., Li, X., MacLellan, W.R. and Crooks, G.M., 2010. Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. *Proceedings of the National Academy of Sciences*, *107*(31), pp.13742-13747.
15. Buckler, R.L., 2011. Opportunities in regenerative medicine. *BioProcessInt*, *9*(3).
16. Brave, M., Farrell, A., Lin, S.C., Ocheltree, T., Miksinski, S.P., Lee, S.L., Saber, H., Fourie, J., Tornoe, C., Booth, B. and Yuan, W., 2010. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. *Oncology*, *78*(3-4), pp.282-288.
17. Drake, A.C., Khoury, M., Leskov, I., Iliopoulou, B.P., Fragoso, M., Lodish, H. and Chen, J., 2011. Human CD34+ CD133+ hematopoietic stem cells cultured with growth factors including Angptl5 efficiently engraft adult NOD-SCID Il2rγ−/−(NSG) mice. *PloS one*, *6*(4).
18. Yuan, X., Wan, H., Zhao, X., Zhu, S., Zhou, Q. and Ding, S., 2011. Brief report: combined chemical treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts. *Stem cells*, *29*(3), pp.549-553.
19. Falanga, V. and Sabolinski, M., 1999. A bilayered living skin construct (APLIGRAF®) accelerates complete closure of hard-to-heal venous ulcers. *Wound Repair and Regeneration*, *7*(4), pp.201-207.
20. Zhang, W., Chen, J., Tao, J., Jiang, Y., Hu, C., Huang, L., Ji, J. and Ouyang, H.W., 2013. The use of type 1 collagen scaffold containing stromal cell-derived factor-1 to create a matrix environment conducive to partial-thickness cartilage defects repair. *Biomaterials*, *34*(3), pp.713-723
21. Zisa, D., Shabbir, A., Mastri, M., Taylor, T., Aleksic, I., McDaniel, M., Suzuki, G. and Lee, T., 2011. Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair. *American Journal of Physiology-Heart and Circulatory Physiology*, *301*(6), pp.H2422-H2432.
22. Voutilainen, M.H., Arumäe, U., Airavaara, M. and Saarma, M., 2015. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease. *FEBS letters*, *589*(24), pp.3739-3748.
23. Kyrou, I., Weickert, M.O., Gharanei, S., Randeva, H.S. and Tan, B.K., 2017. Fibroblast growth factors: new insights, new targets in the management of diabetes. *Minerva endocrinologica*, *42*(3), pp.248-270.
24. Giannelli, G., Mikulits, W., Dooley, S., Fabregat, I., Moustakas, A., ten Dijke, P., Portincasa, P., Winter, P., Janssen, R., Leporatti, S. and Herrera, B., 2016. The rationale for targeting TGF-β in chronic liver diseases. *European journal of clinical investigation*, *46*(4), pp.349-361.
25. Deng, K., Lin, D.L., Hanzlicek, B., Balog, B., Penn, M.S., Kiedrowski, M.J., Hu, Z., Ye, Z., Zhu, H. and Damaser, M.S., 2015. Mesenchymal stem cells and their secretome partially restore nerve and urethral function in a dual muscle and nerve injury stress urinary incontinence model. *American Journal of Physiology-Renal Physiology*, *308*(2), pp.F92-F100.
26. Deng, K., Lin, D.L., Hanzlicek, B., Balog, B., Penn, M.S., Kiedrowski, M.J., Hu, Z., Ye, Z., Zhu, H. and Damaser, M.S., 2015. Mesenchymal stem cells and their secretome partially restore nerve and urethral function in a dual muscle and nerve injury stress urinary incontinence model. American Journal of Physiology-Renal Physiology, 308(2), pp.F92-F100.

27. Nagasawa, T., 2014. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. Journal of molecular medicine, 92(5), pp.433-439.
28. Boros, P. and Miller, C.M., 1995. Hepatocyte growth factor: a multifunctional cytokine. Lancet (British edition), 345(8945), pp.293-295.
29. Zisa, D., Shabbir, A., Mastri, M., Taylor, T., Aleksic, I., McDaniel, M., Suzuki, G. and Lee, T., 2011. Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair. American Journal of Physiology-Heart and Circulatory Physiology, 301(6), pp.H2422-H2432.
30. Voutilainen, M.H., Arumäe, U., Airavaara, M. and Saarma, M., 2015. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease. FEBS letters, 589(24), pp.3739-3748.
31. Kyrou, I., Weickert, M.O., Gharanei, S., Randeva, H.S. and Tan, B.K., 2017. Fibroblast growth factors: new insights, new targets in the management of diabetes. Minerva endocrinologica, 42(3), pp.248-270.
32. Giannelli, G., Mikulits, W., Dooley, S., Fabregat, I., Moustakas, A., ten Dijke, P., Portincasa, P., Winter, P., Janssen, R., Leporatti, S. and Herrera, B., 2016. The rationale for targeting TGF-β in chronic liver diseases. European journal of clinical investigation, 46(4), pp.349-361.
33. Zhang, W., Chen, J., Tao, J., Jiang, Y., Hu, C., Huang, L., Ji, J. and Ouyang, H.W., 2013. The use of type I collagen scaffold containing stromal cell-derived factor-1 to create a matrix environment conducive to partial-thickness cartilage defects repair. Biomaterials, 34(3), pp.713-723.